ME VS AMWL Stock Comparison

Performance

ME
10/100

ME returned -75.03% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AMWL
10/100

AMWL returned -67.06% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Technicals

ME
36/100

ME receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

AMWL
64/100

AMWL receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

ME
10/100

ME has missed earnings 5 times in the last 20 quarters.

AMWL
10/100

AMWL has missed earnings 4 times in the last 20 quarters.

Profit

ME
10/100

Out of the last 14 quarters, ME has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AMWL
10/100

Out of the last 17 quarters, AMWL has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

ME
45/100

ME has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

AMWL
46/100

AMWL has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Sentiment

ME

"Sentiment" not found for ME

AMWL
72/100

AMWL had a bullish sentiment score of 71.78% across Twitter and StockTwits over the last 12 months. It had an average of 5.82 posts, 1.45 comments, and 5.55 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

23andMe Holding Co. Class A Common Stock Summary

Nasdaq / ME

Healthcare

Medical - Diagnostics & Research

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

American Well Corporation Summary

New York Stock Exchange / AMWL

Healthcare

Medical - Healthcare Information Services

American Well Corporation operates as a telehealth software company that enables digital delivery of care for healthcare. The company products offer urgent care; scheduled visits; acute behavioral health; telestroke; pediatrics; retail health, school health, and home settings. Its application offers urgent care; pediatrics; therapy; menopause nutrition; end-stage renal disease and dialysis; dermatology care; behavioral health therapy; and musculoskeletal care. The company also provides telemedicine equipment, including telemedicine carts, peripherals, tyto care, TV kits, tablets, and kiosks. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Power up your portfolio